Who
Clarissa Desjardins
Director
Company insider
Files Form 4 as: Director, Insmed; Director, Xenon Pharmaceuticals.
In numbers
- Trades disclosed
- 13
- Buys
- 2
- Sells
- 0
- Bought
- $202K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 12 Nov 2019
- Last trade
- 13 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 May 2026filed 15 May 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —3,305 | filing |
| 13 May 2026filed 15 May 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —3,305 | filing |
| 21 May 2025filed 22 May 2025 | INSM InsmedBiotechnology | SEC FORM 4 Bought | $75K1,130 at $66.35 | filing |
| 20 May 2025filed 22 May 2025 | INSM InsmedBiotechnology | SEC FORM 4 Bought | $127K1,895 at $66.87 | filing |
| 15 May 2025filed 19 May 2025 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —5,058 | filing |
| 13 May 2024filed 15 May 2024 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —13,162 | filing |
| 11 May 2023filed 15 May 2023 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —13,192 | filing |
| 11 May 2022filed 13 May 2022 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —14,645 | filing |
| 12 May 2021filed 14 May 2021 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —7,558 | filing |
| 1 Jun 2020filed 2 Jun 2020 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 May 2020filed 14 May 2020 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —8,097 | filing |
| 13 Jan 2020filed 14 Jan 2020 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Nov 2019filed 14 Nov 2019 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —5,295 | filing |
News
No headline names them, or the companies they trade most, lately.